J
Juan Lantero-Rodriguez
Researcher at University of Gothenburg
Publications - 36
Citations - 948
Juan Lantero-Rodriguez is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 4, co-authored 12 publications receiving 96 citations. Previous affiliations of Juan Lantero-Rodriguez include Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
Nicholas J. Ashton,Tharick A. Pascoal,Thomas K. Karikari,Andrea Lessa Benedet,Andrea Lessa Benedet,Juan Lantero-Rodriguez,Gunnar Brinkmalm,Anniina Snellman,Michael Schöll,Michael Schöll,Claire Troakes,Abdul Hye,Abdul Hye,Serge Gauthier,Eugeen Vanmechelen,Henrik Zetterberg,Pedro Rosa-Neto,Pedro Rosa-Neto,Pedro Rosa-Neto,Kaj Blennow,Kaj Blennow +20 more
TL;DR: In this paper, the authors developed an ultrasensitive Single Molecule Array (Simoa) for the quantification of plasma p-tau231 which was validated in four independent cohorts (n = 0.588) in different settings, including the full AD continuum and non-AD neurodegenerative disorders.
Journal ArticleDOI
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Joel Simrén,Antoine Leuzy,Thomas K. Karikari,Abdul Hye,Andrea Lessa Benedet,Juan Lantero-Rodriguez,Niklas Mattsson-Carlgren,Michael Schöll,Michael Schöll,Patrizia Mecocci,Bruno Vellas,Magda Tsolaki,Iwona Kłoszewska,Hilkka Soininen,Simon Lovestone,Dag Aarsland,Dag Aarsland,Oskar Hansson,Pedro Rosa-Neto,Eric Westman,Kaj Blennow,Kaj Blennow,Henrik Zetterberg,Nicholas J. Ashton,Nicholas J. Ashton +24 more
TL;DR: In this paper, the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals was investigated.
Journal ArticleDOI
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
Thomas K. Karikari,Andreja Emeršič,Agathe Vrillon,Juan Lantero-Rodriguez,Nicholas J. Ashton,Milica G. Kramberger,Milica G. Kramberger,Julien Dumurgier,Claire Hourregue,Saša Čučnik,Saša Čučnik,Gunnar Brinkmalm,Uroš Rot,Uroš Rot,Henrik Zetterberg,Claire Paquet,Kaj Blennow,Kaj Blennow +17 more
TL;DR: Novel immunoassays targeting N‐terminal and mid‐region p‐tau181 and p-tau217 fragments are available, but head‐to‐head comparison in clinical settings is lacking.
Journal ArticleDOI
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari,Nicholas J. Ashton,Gunnar Brinkmalm,Wagner Scheeren Brum,Andrea Lessa Benedet,Laia Montoliu-Gaya,Juan Lantero-Rodriguez,Tharick A. Pascoal,Marc Suárez-Calvet,Pedro Rosa-Neto,Kaj Blennow,Henrik Zetterberg +11 more
TL;DR: In this article , the authors discuss how new information on the molecular processing of brain p-tau and secretion of specific fragments into biofluids is informing blood biomarker development, enabling the evaluation of preanalytical factors that affect quantification, and informing harmonized protocols for blood handling.
Journal ArticleDOI
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Marta Milà-Alomà,Nicholas J. Ashton,Mahnaz Shekari,Gemma Salvadó,Paula Ortiz-Romero,Laia Montoliu-Gaya,Andrea Lessa Benedet,Thomas K. Karikari,Juan Lantero-Rodriguez,Eugeen Vanmechelen,Theresa A. Day,Armand González-Escalante,Gonzalo Sánchez-Benavides,Carolina Minguillón,Karine Fauria,José Luis Molinuevo,Jeffrey L. Dage,Henrik Zetterberg,Juan Domingo Gispert,Marc Suárez-Calvet,Kaj Blennow +20 more
TL;DR: In this article , the authors found that plasmin(tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline.